ARDS News and Press, Aridis Pharmaceuticals Inc. From 11/10/21

Aridis Pharmaceuticals (NASDAQ:ARDS): Q3 GAAP EPS of -$1.94 misses by $1.44. Revenue of $0.51M beats by $0.21M. Cash and cash equivalents as of September 30, 2021, were approximately $18.2M.  Press Release For further details see: Aridis Pharmaceuticals EPS misses by $1.44, beats o...

Aridis Pharmaceuticals Announces Third Quarter 2021 Results Executed AstraZeneca in-licensing deal of Phase 3-ready antibody, suvratoxumab, in July 2021 Bolstered financial position with approx. $25 million in equity financing in August 2021 PR Newswire LOS GAT...

Aridis Pharmaceuticals Announces Second Quarter 2021 Results -- In-licensed Phase 3-ready antibody, suvratoxumab, from AstraZeneca -- Raised approximately $25 million in equity financing -- Confirmed that SARS-CoV-2 antibody combination AR-712 is active against the Delta...

Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market PR Newswire LOS GATOS, Calif. , Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discove...

Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) traded at a new 52-week low today of $4.59. So far today approximately 832,000 shares have been exchanged, as compared to an average 30-day volume of 258,000 shares. Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is enga...

Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC) CoVIC's animal efficacy data shows that Aridis' AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that hav...

Gainers: Freeline Therapeutics (FRLN) +88%, Cytokinetics CYTK +49%, NRx Pharmaceuticals NRXP +37%, Allied Healthcare Products (AHPI) +19%, Aethlon Medical (AEMD) +16%.Losers: China SXT Pharmaceuticals (SXTC) -21%, Atossa Therapeutics (ATOS)&#x...

Aridis Pharmaceuticals (ARDS) announces that it has entered into an exclusive worldwide licensing agreement with AstraZeneca (AZN) to in-license suvratoxumab, in a deal worth as much as $126M. Suvratoxumab is a late-stage monoclonal antibody ((mAb)) candidate being developed for preventi...

Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca PR Newswire LOS GATOS, Calif. , July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered...

CIPhotos/iStock via Getty Images Shares of Aridis Pharmaceuticals ([[ARDS]] -18.5%) are down sharply in afternoon trading, a day after shares surged following the release of encouraging preclinical data for its COVID-19 antibody cocktail. In an animal model, AR-712 was effective in neutralizi...